论文部分内容阅读
目的评估阿卡波糖对2型糖尿病患者血清nesfatin-1水平及糖、脂代谢的影响。方法对符合纳入标准的60例2型糖尿病患者进行原降糖药物调整,当空腹血糖(FPG)、餐后2 h血糖(2hPG)分别控制在6～8、8～10 mmol/L后,将所有患者随机分为2组:试验组在原降糖方案基础上给予阿卡波糖片,对照组进行空白对照。试验周期12周。结果试验组与对照组基线水平差异无统计学意义(P>0.05)。试验组治疗前后nesfatin-1水平上升(P<0.01),FPG、2hPG、糖化血红蛋白(HbA1c)、体质量指数(BMI)、稳态模型胰岛素抵抗指数(HOMA-IR)、甘油三酯(TG)及总胆固醇(TC)均较前降低(P<0.01或P<0.05),对照组仅2hPG较前下降(P<0.01)。治疗后行协方差分析结果显示,试验组nesfatin-1水平较对照组升高(P<0.05),FPG、2hPG、HbA1c、空腹胰岛素(FPI)、HOMA-IR、TG及TC均较对照组降低(P<0.05或P<0.01)。结论阿卡波糖可升高2型糖尿病患者血清nesfatin-1水平,并有效改善糖脂代谢。
Objective To evaluate the effect of acarbose on serum nesfatin-1 and glucose and lipid metabolism in type 2 diabetic patients. Methods Sixty patients with type 2 diabetes mellitus were enrolled in this study. When FPG and 2hPG were controlled at 6 ~ 8 and 8 ~ 10 mmol / L respectively, All patients were randomly divided into two groups: the experimental group was given acarbose based on the original hypoglycemic regimen, and the control group was blank control. The test period is 12 weeks. Results The baseline level of experimental group and control group had no significant difference (P> 0.05). The levels of nesfatin-1, FPG, HbA1c, BMI, HOMA-IR, triglyceride (TG) in the experimental group before and after treatment increased (P <0.01 or P <0.05), while the control group only 2 hPG decreased compared with the previous (P <0.01). After treatment, covariance analysis showed that the level of nesfatin-1 in test group was significantly higher than that in control group (P <0.05), FPG, 2hPG, HbA1c, FPI, HOMA-IR, TG and TC were lower than those in control group (P <0.05 or P <0.01). Conclusion Acarbose can increase the level of serum nesfatin-1 in patients with type 2 diabetes and effectively improve glucose and lipid metabolism.